L2-7001 + antiretroviral therapy

**L2-7001 + antiretroviral therapy** is a combination regimen under investigation for the treatment of HIV-1 infection. **L2-7001** is a long-acting injectable (LAI) microsphere formulation of **cabotegravir**, an HIV-1 integrase strand transfer inhibitor (INSTI). Developed by **L2 Bioscience**, L2-7001 utilizes a proprietary microsphere technology to enable sustained release of cabotegravir, aiming to extend the dosing interval and improve treatment adherence for individuals living with HIV-1. In clinical development, this combination is being evaluated for its ability to maintain viral suppression in treatment-experienced patients. The regimen represents a shift towards long-acting therapeutic options that reduce the daily pill burden associated with conventional oral antiretroviral therapy (ART).

Other names

cabotegravir long-acting injectable microspheres + antiretroviral therapyL2-7001 plus ARTL-2-7001 plus ARTL 2-7001 plus ART